Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib in Japanese Patients With NSCLC
NCT04402008Phase 2Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Jun 2020
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC), sponsored by Spectrum Pharmaceuticals, Inc.. Started Jun 2020; status: terminated.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04402008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402008.